Industry Projects - View By Region

Latest Projects

Idhifa (enasidenib) for the Treatment of Acute Myeloid Leukaemia (AML)

Idhifa (enasidenib) is an isocitrate dehydrogenase 2 (IDH2) enzyme inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia...

Idhifa (enasidenib) for the Treatment of Acute Myeloid Leukaemia (AML)

MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C

MAVYRET™ (glecaprevir/pibrentasvir) was developed by US-based biopharmaceutical company AbbVie as a pan-genotypic treatment for adults suffering from chronic hepatitis C virus (HCV)...

MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C

Vosevi™ for the Retreatment of Chronic Hepatitis C Virus Infection

Vosevi™ (Sofosbuvir/Velpatasvir/Voxilaprevir) is a direct-acting antiviral (DAA) indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults with genotypes one to...

Vosevi™ for the Retreatment of Chronic Hepatitis C Virus Infection

Tremfya (guselkumab) for the Treatment of Plaque Psoriasis

Tremfya™ (guselkumab) is a biologic approved for the treatment of adults living with moderate to severe plaque psoriasis....

Tremfya (guselkumab) for the Treatment of Plaque Psoriasis

Endari for the Treatment of Sickle Cell Disease

Endari™ is an orally-administered powder form of amino acid L-glutamine indicated for the treatment of sickle cell disease....

Endari for the Treatment of Sickle Cell Disease

Haegarda for the Preventive Treatment of Hereditary Angioedema

Haegarda® (C1 Esterase Inhibitor) a subcutaneous prophylactic therapy indicated for the prevention of hereditary angioedema (HAE) attacks in adolescent and adult...

Haegarda for the Preventive Treatment of Hereditary Angioedema

Baxdela™ (delafloxacin) for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Baxdela™ (delafloxacin) is a fluoroquinolone antibiotic drug indicated for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI). The drug was discovered...

Baxdela™ (delafloxacin) for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Zykadia (Ceritinib) Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)

Zykadia (Ceritinib / LDK378) is an inhibitor of anaplastic lymphoma kinase (ALK) indicated for treatment of non-small cell lung cancer...

Zykadia (Ceritinib) Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)

Mydayis for the Treatment of Attention Deficit Hyperactivity Disorder

Mydayis is a CNS stimulant drug indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 13 years and...

Mydayis for the Treatment of Attention Deficit Hyperactivity Disorder

Truxima (rituximab) for the Treatment of Cancer

ruxima™ (rituximab) is the first biosimilar monoclonal antibody (mAb) approved for the treatment of haematological cancers, including diffuse large B-cell lymphoma, follicular lymphoma,...

Truxima (rituximab) for the Treatment of Cancer

Kevzara (sarilumab) for the Treatment of Rheumatoid Arthritis

Kevzara® (sarilumab) is a human monoclonal antibody indicated for the treatment of adult patients with moderate to severely active rheumatoid arthritis (RA)....

Kevzara (sarilumab) for the Treatment of Rheumatoid Arthritis

Tecentriq (atezolizumab) for the Treatment of Metastatic Urothelial Carcinoma (mUC)

Tecentriq® (atezolizumab) is a monoclonal antibody designed to bind with a protein called PD-L1....

Tecentriq (atezolizumab) for the Treatment of Metastatic Urothelial Carcinoma (mUC)

Dinutuximab beta for the Treatment of Neuroblastoma

Dinutuximab beta is an anti-GD2 monoclonal antibody indicated for the treatment of neuroblastoma in patients aged one year and...

Dinutuximab beta for the Treatment of Neuroblastoma

Alunbrig (brigatinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

Alunbrig (brigatinib) is a tyrosine kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC)....

Alunbrig (brigatinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

Radicava (edaravone) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Radicava™ (edaravone) is a neuroprotective agent indicated for the treatment of amyotrophic lateral sclerosis (ALS)....

Radicava (edaravone) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Imfinzi (durvalumab) for the Treatment of Metastatic Urothelial Carcinoma (mUC)

Imfinzi™ (durvalumab) is a monoclonal antibody (mAb) indicated for the treatment of metastatic urothelial carcinoma (mUC)....

Imfinzi (durvalumab) for the Treatment of Metastatic Urothelial Carcinoma (mUC)

Rydapt (midostaurin) for the Treatment of Acute Myeloid Leukaemia and Systemic Mastocytosis

Rydapt® (midostaurin) is a multi-targeted inhibitor of multiple kinases including FMS-like tyrosine kinase 3 mutation-positive (FLT3+) and KIT approved for the treatment of acute myeloid...

Rydapt (midostaurin) for the Treatment of Acute Myeloid Leukaemia and Systemic Mastocytosis

Ingrezza (valbenazine) for the Treatment of Tardive Dyskinesia

Ingrezza (valbenazine) is first and only US Food and Drug Administration (FDA) approved vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with...

Ingrezza (valbenazine) for the Treatment of Tardive Dyskinesia

Austedo (deutetrabenazine) for the Treatment of Chorea

Austedo™ (deutetrabenazine) is a vesicular monoamine transporter 2 (VMAT 2) inhibitor indicated for the treatment of chorea associated with Huntington’s disease...

Austedo (deutetrabenazine) for the Treatment of Chorea

Zejula (niraparib) for the Treatment of Ovarian Cancer

Zejula™ (Niraparib) is a poly adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitor approved for the treatment of adult patients with ovarian cancer....

Zejula (niraparib) for the Treatment of Ovarian Cancer

Xadago (safinamide) for the Treatment of Parkinson’s Disease (PD)

Xadago® (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor indicated for the treatment of Parkinson's disease....

Xadago (safinamide) for the Treatment of Parkinson’s Disease (PD)